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Motor neuron disease affects upper motor neurons in the brain and lower motor neurons in the 
spine and causes muscle weakness, atrophy, difficulty swallowing, respiratory failure, and death. 
The development of effective interventions for adult motor neuron diseases, such as amyotrophic 
lateral sclerosis (ALS) and spinal and bulbar muscular atrophy (SBMA, also known as 
Kennedy’s disease), remains a challenge. To date, many clinical trials have been conducted and 
most of them have failed. In this thesis, we analyzed a previous large ALS clinical trial using 
total drug exposure and searched for biomarkers that correctly reflect dysphagia in SBMA to 
help achieve more efficient clinical trials for motor neuron disease in the future.   
 In my first article, we used a database of the clinical trial of ceftriaxone. Ceftriaxone, a β-
lactam antibiotic, has been shown to increase the glutamate transporter that clears glutamate 
from the synapse. In the clinical trial of ceftriaxone for ALS, 514 participants in the United 
States and Canada were enrolled. Of these, 341 participants were randomly allocated to 
ceftriaxone and 173 to placebo for at least 12 months. The trial did not show significant clinical 
efficacy; however, treatment adherence may have masked potential efficacy. We analyzed the 
effect of total drug exposure using a random slopes regression model that included age, sex, 
disease duration, riluzole, El Escorial Criteria, and baseline functional scores as fixed effects and 
intercept and slope as random effects. We found total ceftriaxone exposure analysis did not show 
overall efficacy of ceftriaxone. We concluded that failed clinical trials with intervention-
adherence problems may need total drug exposure analysis to assess potential effect of the 
medication. 
 In my second article, we analyzed the results of the videofluoroscopic swallowing study 
(VFSS) in 111 consecutive genetically confirmed patients with SBMA and 53 age- and sex-
matched healthy controls.  Difficulty swallowing (dysphagia) is a major symptom of motor 
neuron disease, and often leads to life-threatening events such as aspiration pneumonia and 
suffocation. Although bulbar dysfunction is an important prognostic factor, reliable outcome 
measures have not been fully established to evaluate dysphagia in motor neuron disease. Out of 
more than 40 radiographic symptoms, the most pertinent abnormal findings in patients with 
SBMA include vallecular residue after swallow (residue just behind the tongue base), nasal 
penetration, and insufficient tongue movement (P < 0.001 for each) as compared with healthy 
controls. Quantitative analyses showed pharyngeal residue after initial swallowing, oral residue 
after initial swallowing, multiple swallowing sessions, and penetration–aspiration scale were 
significantly worse in patients (P ≤ 0.005 for each) as compared with healthy subjects. In 
patients with SBMA, laryngeal penetration was observed more frequently in subjects without 
subjective dysphagia. We revealed that dysphagia of SBMA is characterized by impaired tongue 
movement and nasal penetration, followed by pharyngeal residues, resulting in multiple 
swallowing sessions and laryngeal penetration. We concluded that pharyngeal residue and 
penetration-aspiration scale reflect major features of dysphagia in patients with SBMA. 
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ABSTRACT 
 
Objective Ceftriaxone, a β-lactam antibiotic, has been shown to increase the mRNA for a 
glutamate transporter that clears glutamate from the synapse. In a clinical trial of ceftriaxone, 
514 patients with ALS were enrolled in an efficacy study. The trial did not show significant 
clinical efficacy; however, treatment adherence may have masked potential efficacy. We sought 
to assess whether ceftriaxone total drug exposure had any effect on the rate of decline in function 
compared with placebo through 1-year follow-up. 
Methods The outcome measures for post-hoc analysis were the same as those in the primary 
trial: difference between the treatment and placebo groups in rate of decline in function as 
measured by ALSFRS-R; secondary outcome measures included vital capacity and muscle 
strength. We set total drug exposure as a time-varying covariate. The effect of total drug 
exposure was analysed using a random slopes regression model that included age, sex, disease 
duration, riluzole, El Escorial criteria and baseline functional scores as fixed effects and intercept 
and slope as random effects. 
Results Of the participants in the ceftriaxone arm, 42.2 percent received less than half the full 
dosage for 1 year. No favorable correlation was found between total ceftriaxone exposure and 
ALSFRS-R changes. Total drug exposure analysis using the random slopes regression model did 
not show any effect (p = 0.714).  
Conclusions Total drug exposure analysis did not show overall efficacy of ceftriaxone. Failed 
clinical trials with intervention-adherence problems may benefit from total drug exposure 
analysis to assess potential effect of the medication. 
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INTRODUCTION 
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neuromuscular disease that  
affects mainly motor neurons of the brain and spine and results in progressive muscle weakness, 
atrophy, and respiratory failure. 1,2 ALS is more common in people 60 to 69 years of age than in 
other age groups, and the prevalence of patients with a definite diagnosis of ALS is 3.9 cases per 
100,000 people in the US general population.3 Median survival was reported to be 36 months 
after the first symptom, although 10 percent of the patients were alive more than 10 years later.4 
Current approved medications, riluzole, and edaravone in Japan, have had limited impact on 
disease progression.5,6 With the recent progress in causative gene discoveries in ALS7,8 and 
clinical trials of gene silencing and stem cell transplantation,9,10 increasing attention has focused 
on ALS therapy development. Many clinical trials have been performed and most of them have 
failed to show effective results. The reasons for the futility of these trials are multifaceted: the 
central disease mechanism that causes neurodegeneration is unclear; animal models that 
correctly recapitulate human disease mechanisms, especially of sporadic ALS cases, are lacking; 
disease heterogeneity, both genetically and phenotypically, is a challenge; a high participant 
drop-out rate in clinical trials due to short life expectancy is common, and target biomarkers are 
lacking.11 Failed clinical trials may, however, suggest important avenues to future success. 
Ceftriaxone, a β-lactam antibiotic, has been shown to increase the level of a glutamate 
transporter that clears glutamate from the synapse and decreases glutamate excitotoxicity in 
rodent brains and in human astrocyte cultures.12-14 Ceftriaxone also slowed disease progression 
and prolonged survival in a mouse model of ALS.13  
In the clinical trial of ceftriaxone for ALS, 514 patients with ALS in the United States and 
Canada were enrolled.15 Of these, 341 participants were randomly allocated to ceftriaxone and 
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173 to placebo for at least 12 months. All participants were asked to stay in the study until the 
last enrolled participant completed 12 months of treatment. On average, participants receiving 
ceftriaxone remained on drug for a mean of 14.2 months (SD 11.7), whereas participants 
receiving placebo remained on drug for 12.3 months (SD 9.2). Drug exposure variance was also 
caused by the trial suspension due to futility, because of failure of the drug to show significant 
efficacy. However treatment adherence may have masked the potential efficacy of ceftriaxone 
because long treatment duration and adverse events can result in suspending or discontinuing the 
medication. In this post-hoc study, which focused on total drug exposure, our objectives were as 
follows: (1) to assess whether ceftriaxone total drug exposure had any positive effect on the rate 
of slope decline in function compared with the placebo arm; (2) to describe the potential effect of 
total ceftriaxone exposure; (3) to explore the potential effect of ceftriaxone by missing data 
analysis.  
 
METHODS 
Ceftriaxone trial 
We conducted a post-hoc analysis of a randomised, double-blinded, placebo-controlled, 
multicenter, phase 3 trial of the safety and efficacy of ceftriaxone versus placebo for the 
treatment of ALS, which was conducted at 59 clinical sites in the United States and Canada 
between 2006 and 2012.15 This study originally consisted of three stages: stage 1 
(pharmacokinetics in the plasma and cerebrospinal fluid); stage 2 (safety over 20 weeks); and 
stage 3 (efficacy).16 In stage 3, new participants were randomly assigned (2:1) to 4 grams of 
ceftriaxone or placebo. Participants who were in stage 1 and 2 were also randomly allocated 
(2:1) to ceftriaxone or placebo at each stage and continued the trial medication in a blinded 
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fashion at stage 3.15 For the ceftriaxone group participants in stage 3, which we analysed in this 
post-hoc analysis, 2 grams of ceftriaxone or placebo were administered twice daily to the patient 
through a central venous catheter by a trained caregiver in the home. The last participant enrolled 
in December 2011, but the study was stopped for futility by the data safety monitoring board in 
July 2012 before all patients had received full treatment.15 This clinical trial protocol was 
approved by the institutional review board at each participating centre, and all participants 
provided written informed consent. The trial is registered at ClinicalTrials.gov, number 
NCT00349622. The study was performed in accordance with the Declaration of Helsinki and 
Good Clinical Practice. This post-hoc analysis was approved by the steering committee of the 
clinical trial.  
 
Outcome measures 
The primary outcome measures for this post-hoc analysis were the same as those in the primary 
trial: difference between the treatment and placebo groups in rate of decline in function as 
measured by ALS Functional Rating Scale-revised (ALSFRS-R).17 Secondary outcome measures 
included vital capacity, muscle strength measured using handheld dynamometry (HHD), the 
Amyotrophic Lateral Sclerosis Specific Quality of Life (ALSSQOL) questionnaire18 and the 
Caregiver Burden Inventory (CBI) 19 (Supplementary methods). 
 
Total drug exposure 
Total drug exposure in ceftriaxone group participants was calculated by the sum of daily 
exposure to ceftriaxone or placebo, which ranged from 0 gram to 4 grams a day. We calculated 
the total amount of ceftriaxone during the 12-month clinical trial observation period, even though 
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some patients had drug holidays because of side effects, etc. The maximum dosage of 
ceftriaxone for 1 year was 1440 grams (4 grams*30 days*12 months). In the placebo group, 
participants were given a paediatric multivitamin for infusion to colour-match the ceftriaxone 
syringes. The amount of placebo infusion was used for comparison in total drug exposure 
analyses. 
 
Statistical methods 
We used the same data set as the primary analyses of the ceftriaxone trial. First, we reconfirmed 
the primary analysis results, which were based on the intention-to-treat principle. Second, a 
histogram, a scatter plot and a three-dimensional plot regarding total drug exposure were 
constructed (figure 1, 2 and 3).  Third, the effect of total drug exposure was analysed using a 
random slopes regression model that included age, sex, disease duration, riluzole, El Escorial 
Criteria and a baseline functional score as fixed effects and intercept and slope as random effects 
(supplementary method, and table 1). Total drug exposure was set as a time-varying covariate. 
The slopes of the functional score (eg, ALSFRS-R) in 120 gram-unit drug exposure was 
compared between the two groups. The analyses were conducted only for continuous or ordinal 
functional variables to make them appropriate for our model. Covariance structure for random 
effects was set as unstructured. We analysed the relationship between mean daily functional 
changes and mean daily drug exposure (supplementary table 1). The effect of mean daily drug 
exposure was analysed using a random slopes regression model that included age, sex, disease 
duration, riluzole, El Escorial Criteria20 and a baseline functional score as fixed effects and 
intercept and slope as random effects. The dependent variable of the mean daily drug exposure 
analysis is the change per day [eg, (ALSFRS-R score of any visit – ALSFRS-R score of the 
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previous visit) / (duration between the two visits)].  We set mean daily drug exposure (total drug 
exposure between the two visits) as a time-varying covariate as we did in total drug exposure 
analyses. Mixed-effects model repeated measures (MMRM) analysis was used to evaluate the 
effect of missing data and to speculate on the potential effect of ceftriaxone by comparing 
adjusted mean of ceftriaxone arm with that of placebo arm at each time point (figure 4, 
supplementary table 2 and supplementary figure). All the statistical analyses were performed 
using SAS (version 9.4; SAS Institute Cary Inc., CA, USA). For all tests, a p value of <0.05 was 
considered statistically significant. 
 
RESULTS 
Distribution of total ceftriaxone exposure 
Of 340 analysed participants in the ceftriaxone arm, 184 discontinued the study (84 because of 
an adverse event, 31 because of disease progression); 156 completed the study. Of 173 analysed 
participants in the placebo arm, 102 discontinued the study (32 because of an adverse event, 16 
because of disease progression); 71 completed the study. Of those receiving ceftriaxone, 22.7 
percent of the patients had 0-360 grams of drug exposure (0 to 3 months equivalent dosage),  
19.5 percent of the patients had 361-720 grams of drug exposure (3 to 6 months equivalent 
dosage),  21.8 percent of the patients had 721-1080 grams of drug exposure (6 to 9 months 
equivalent dosage), and 38.4 percent of the patients had 1081-1440 grams of drug exposure (9 to 
12 months equivalent dosage) for the 1-year follow-up duration. Dose distribution of ceftriaxone 
group was similar to that of placebo group (figure 1).  
 
ALSFRS-R changes and total ceftriaxone exposure 
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If the total ceftriaxone exposure affects functional severity positively in spite of disease course, 
the ALSFRS-R changes at drug suspension will be less severe in the patients with high total 
exposure. We calculated the ALSFRS-R changes in participants in the ceftriaxone arm (n = 340) 
and presented the results in a scatter plot with total ceftriaxone exposure. No positive correlation 
was found between total ceftriaxone exposure and ALSFRS-R changes at drug suspension (r2 = 
0.081; figure 2). 
 
Three dimensional plot of total drug exposure, follow-up time and ALSFRS-R 
changes 
We analysed the difference between the participants in the ceftriaxone arm and those in the 
placebo arm using total drug exposure, time of drug suspension and ALSFRS-R changes at the 
drug suspension. We used time of drug suspension instead of 12 months (full observation 
duration) to find out the effect of total drug exposure on both the ALSFRS-R changes and drug 
suspension. The three-dimensional plot shows the relationships among three parameters: time of 
drug suspension (X-axis), total ceftriaxone exposure (Y-axis), and ALSFRS-R changes at the 
drug suspension (Z-axis) (figure 3A). The overall contours of the ceftriaxone group and the 
placebo group were almost identical, even though participant numbers differ between two groups, 
indicating that total ceftriaxone exposure is not affecting ALSFRS-R changes at the drug 
suspension compared with the placebo arm (figure 3 B, C). 
 
Total drug exposure analysis using a random slopes regression model 
Total ceftriaxone exposure analysis using a random slopes regression model of decline in 
function as measured by ALSFRS-R that includes age, sex, disease duration, riluzole, El Escorial 
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Criteria and a baseline functional score did not show potential efficacy (p = 0.714, table 1A). 
Table 1B shows similar analyses for secondary endpoints including vital capacity, HHD muscle 
strength of upper extremities and lower extremities, ALSSQOL and CBI. Only CBI showed a 
worsening trend in the ceftriaxone arm (p = 0.062). 
 
Mean daily drug exposure analysis using a random slopes regression model 
We analysed the relation between “mean daily ALSFRS-R change between any two visits: 
(ALSFRS-R change) / (days between two visits)” and “mean daily drug exposure: (drug 
exposure between the visits) / (days between two visits)”. We did this analysis because total 
ceftriaxone exposure might be affected by drug suspensions at drug holidays or because of 
temporary side effects. Mean daily drug exposure analysis using a random slopes regression 
model of decline in function as measured by ALSFRS-R that includes age, sex, disease duration, 
riluzole, El Escorial Criteria and baseline ALSFRS-R score did not show significant efficacy (p 
= 0.066, supplementary table 1). No significant efficacy was shown in similar analyses for 
secondary endpoints (supplementary table 1). 
 
Mixed-effects model repeated measures (MMRM) analysis 
We evaluated the effect of missing data and speculated on the potential effect of ceftriaxone. By 
analyzing ALSFRS-R changes per month for 6 and 12 months, using MMRM, a significant  
difference of least square mean was found only at the point of 12 months (p = 0.038, figure 4). 
Otherwise, no significant differences were found in other endpoints (supplementary 
supplementary table 2). 
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DISCUSSION 
In this study, our goal was to assess whether ceftriaxone total drug exposure had any effect on 
function by post-hoc analyses. First, we found that total drug exposure of ceftriaxone group was 
similar to that of placebo group. Of the participants in the ceftriaxone arm, 42.2 percent received 
less than half the full dosage for 1 year. Second, we could not find any positive correlations 
between total ceftriaxone exposure and ALSFRS-R changes at drug suspension. Third, the three-
dimensional plot of time of drug suspension (X-axis), total ceftriaxone exposure (Y-axis), and 
ALSFRS-R changes at the drug suspension (Z-axis) showed no obvious morphological 
differences between participants in the ceftriaxone arm and those in the placebo arm. Fourth, 
total drug exposure analysis using a random slopes regression model that included age, sex, 
disease duration, riluzole, El Escorial Criteria and baseline ALSFRS-R score did not show 
significant potential efficacy of ceftriaxone. We found that the Caregiver Burden Inventory 
(CBI) was worse in the ceftriaxone arm by total drug exposure analysis. This result may be 
explained by diarrhea, a common side effect of ceftriaxone that results in further burdens for 
caregivers. Last, we also explored the potential effect of ceftriaxone by missing data analysis. 
Mixed-effects model repeated measures (MMRM) analysis revealed significant slope difference 
only at the point of 12 months (p = 0.038). Given the results of the other analyses, excepting 
MMRM, we concluded the overall ceftriaxone total drug exposure had no significant effect in 
patients with ALS. 
 Recently, MMRM has become commonly used for missing data analyses. In a sensitivity 
analysis of 48 clinical trial datasets obtained from 25 New Drug Applications submitted for 
neurological and psychiatric drug products, MMRM analysis appears to be a superior approach 
in controlling false-positive error rates and minimizing biases, as compared with last observation 
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carried forward (LOCF) analysis of covariance.21 Our data showed marginal significance only at 
12 months and no significant efficacy was detected at other time points (supplementary table 2). 
Given that this is a post-hoc analysis, our evaluation of the overall statistical results of this 
medication is that it is not potent enough to induce significant clinical efficacy. 
The reasons for failure in clinical trials for patients with ALS can be classified by several 
factors. First, superoxide dismutase-1 (SOD1) transgenic rodent models do not recapitulate 
sporadic disease in humans and minimally replicate mutant SOD1 familial ALS.22, 23 Further, the 
central pathophysiology of neurodegeneration in ALS remains unknown.24 In addition, we 
should consider pharmacological aspects of the investigational medication, such as interaction of 
riluzole, appropriate dosage, pharmacokinetic or pharmacodynamics markers, cerebrospinal fluid 
penetration or bioavailability, and biomarker relevance.11,25 In terms of trial design, disease 
heterogeneity and differences in study population between phase 2 and phase 3 trials can cause 
trial failures.26 Data from failed clinical trials is valuable to revisit because of the potential for 
participant enrichment, which may contribute to the success of future studies. This was seen in 
the case of edaravone, which was recently approved in Japan after employing a strict enrichment 
strategy.27 In addition, potential biomarkers can be found in data from previous trials.26 
The ceftriaxone clinical trial in ALS was conducted at more than 50 centres and with 
more than 500 participants. Intravenous infusion of ceftriaxone was performed twice daily 
through a central venous catheter at home for at least 12 months. Given the daily multiple 
infusions for the long duration and the risk of catheter infection, cholelithiasis28 and renal 
dysfunction29 caused by ceftriaxone, total drug exposure varies for the individual patient, which 
we confirmed in our study. Drug exposure variance was also a result of the trial suspension due 
to futility. Therefore, the potential effect of ceftriaxone should be reevaluated by total drug 
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exposure; our current study revealed no significant effects by relevant analyses, except for the 
missing data analysis using MMRM. These results suggest that ceftriaxone tolerability and early 
trial suspension are not the causes of the trial failure.  
 The strength of this post-hoc analysis is the use of a new parameter, total drug exposure, 
which is closely related to drug adherence and patient retention. In Parkinson’s disease, a 
cumulative dose of dopamine agonists correlated to vulvopathy.30 However, use of total drug 
exposure in ALS clinical trials has rarely been conducted.31 Since ALS is a life-limiting 
neuromuscular disease that results in progressive muscle weakness and poor quality of life, many 
patients in a clinical trial for ALS tend to withdraw from trial participation, decrease the dose, or 
stop taking the medication altogether in the midst of the study. In line with these observations, 
we conducted this post-hoc analysis using total ceftriaxone exposure. We successfully conducted 
total drug exposure analyses that did not show significant potential efficacy of ceftriaxone. The 
other strength of this study is that the ceftriaxone trial has long-term longitudinal data of more 
than 500 patients with ALS, one of the largest ALS interventional trials to date. The limitations 
of our study include the fact that this is a post-hoc analysis. Prespecified secondary analyses are 
ideal to avoid false-positive results (type I error). However, given that there are few clinically 
useful medications for ALS, greater effort should be devoted toward reviewing previous studies 
to find potential effects of the intervention and to design comparable but more efficient clinical 
trials for the future. We suggest that total drug exposure analysis as a potential prespecified 
secondary analysis would be valuable for a future clinical trial in ALS with a long follow-up 
duration. 
In summary, our study revealed that a total ceftriaxone exposure analysis using a random 
slopes regression model did not show overall efficacy of ceftriaxone. Failed clinical trials with 
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patient adherence problems may benefit from total drug exposure post-hoc analysis to eliminate 
false-negative results and to elucidate the potential efficacy of the study medication. 
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Figure legends 
 
Figure 1 Distribution of total ceftriaxone exposure 
Of 340 analysed participants in the ceftriaxone arm, 22.7 percent of the patients had 0 to 3 
months equivalent dosage,  19.5 percent had 3 to 6 months equivalent dosage,  21.8 percent had 
6 to 9 months equivalent dosage, and 38.4 percent had 9 to 12 months equivalent dosage for the 
1-year follow-up duration. Dose distribution of ceftriaxone group was similar to that of placebo 
group. 
 
Figure 2 ALSFRS-R changes and total ceftriaxone exposure 
ALSFRS-R changes at drug suspension (n = 340) and total ceftriaxone exposure shown in a 
scatter plot. No positive correlation was found between total ceftriaxone exposure and ALSFRS-
R changes at drug suspension (r2 = 0.081). 
 
Figure 3 Three-dimensional plots of total drug exposure, follow-up time and ALSFRS-R changes 
The three-dimensional plot shows the relationships among three parameters: time of drug 
suspension (X-axis), total drug exposure (Y-axis), and ALSFRS-R changes at drug suspension (Z-
axis) (A). The overall contours of the ceftriaxone group and the placebo group were not 
morphologically different even though participant numbers are different between the ceftriaxone 
arm (n = 340) and the placebo arm (n = 173), indicating total ceftriaxone exposure is not 
affecting ALSFRS-R changes at  drug suspension compared with the placebo arm (B, C). 
 
Figure 4 Mixed-effects model repeated measures (MMRM) analysis in ALSFRS-R 
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The effect of missing data was analysed by the mixed-effects model repeated measures (MMRM) 
approach. By analysing ALSFRS-R changes per month for 6 and 12 months, a significant  
difference of least square mean was found only at the point of 12 months (p = 0.038). 
 
Supplementary figure Mixed-effects model repeated measures (MMRM) analysis in secondary 
endpoints 
The effect of missing data was analysed by the mixed-effects model repeated measures analysis. 
No significant differences of least square mean were found in primary and secondary endpoints 
(changes per month for 1, 4, 8 and 12 months). Detailed p-values are shown in supplementary 
table 2. ALSSQOL, Amyotrophic Lateral Sclerosis Specific Quality of Life.  
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Table Total drug exposure analysis using a random slope regression model as measured by 
ALSFRS-R (A) and secondary endpoints (B) 
(A) 
Ceftriaxone  
n=340 
Placebo  
n=173 
Difference p 
Intention-to-treat analysis 
(primary analysis) 
-1.13 (0.04) -1.22 (0.06) 0.09 (0.08) 0.237 
Total ceftriaxone exposure 
analysis (post-hoc analysis) 
-1.08 (0.07) -1.04 (0.08) -0.04 (0.11) 0.714 
 
(B) 
Ceftriaxone  
n=340 
Placebo  
n=173 
Difference p 
Percent vital capacity -3.04 (0.23) -3.49 (0.27) 0.45 (0.35) 0.201 
Upper limb muscle strength -9.99 (0.70) -8.45 (0.83) -1.54 (1.08) 0.155 
Lower limb muscle strength -9.13 (0.68) -8.39 (0.85) -0.74 (1.09) 0.498 
ALSSQOL -4.76 (0.50) -4.22 (0.59) -0.54 (0.77) 0.485 
Caregiver Burden Inventory 1.72 (0.12) 1.37 (0.14) 0.35 (0.19) 0.062 
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Data are mean  (standard error). The mean values are change from baseline through 1-year 
follow-up in units per month for intention-to-treat analysis, and per 120-gram unit exposure 
for total drug exposure analysis. 
ALSFRS-R, Amyotrophic Lateral Sclerosis Functional Rating Scale-revised; ALSSQOL, 
Amyotrophic Lateral Sclerosis Specific Quality of Life. 
 
Supplementary table 1 Mean daily drug exposure analysis using a random slope regression 
model as measured by ALSFRS-R and secondary endpoints 
 
Ceftriaxone  
n=340 
Placebo  
n=173 
Difference p 
ALSFRS-R 
0.000019 
(0.000109) 
0.000373 
(0.000159) 
-0.000355 
(0.000193) 
0.066 
% Slow vital capacity 
-0.00254 
(0.00104) 
-0.00411 
(0.00183) 
0.00157 
(0.00210) 
0.454 
Upper limb muscle strength 
-0.00048 
(0.00118) 
0.00091 
(0.00207) 
-0.00139 
(0.00239) 
0.560 
Lower limb muscle strength 
-0.00056 
(0.00140) 
0.00046 
(0.00227) 
-0.00102 
(0.00267) 
0.701 
ALSSQOL 
-0.00382 
(0.00189) 
-0.00357 
(0.00293) 
-0.00025 
(0.00350) 
0.943 
Caregiver Burden Inventory 0.00028 (0.00034)
0.00018 
(0.00058) 
0.00011 
(0.00067) 
0.871 
Data are mean (standard error). The mean values are change from baseline through 1 year of 
follow-up per 120 g unit for total drug exposure analysis. ALSFRS-R, revised Amyotrophic lateral 
sclerosis functional rating scale; ALSSQOL, Amyotrophic Lateral Sclerosis Specific Quality of Life. 
  
Supplementary table 2 Mixed-effects model repeated measures (MMRM) approach for 
ALSFRS-R and secondary endpoints 
 
Time point 
Least square mean 
difference 
95%CI p 
ALSFRS-R 
1 month -0.354  (-1.532, 0.824) 0.556 
4 months -0.016 (-1.218, 1.185) 0.979 
8 months 0.358 (-0.876, 1.592) 0.569 
12 months 1.376 (0.076, 2.676) 0.038 
% Slow vital capacity 
1 month -0.076  (-3.519, 3.367) 0.965 
4 months 0.974 (-2.602, 4.549) 0.593 
8 months 0.252 (-3.680, 4.185) 0.900 
12 months 3.093 (-1.364, 7.551) 0.174 
Upper limb muscle strength 
1 month -0.491  (-8.990, 8.008) 0.910 
4 months -2.140 (-11.245, 6.965) 0.645 
8 months -4.304 (-14.846, 6.238) 0.423 
12 months 2.739 (-9.580, 15.058) 0.663 
Lower limb muscle strength 
1 month -1.296 (-12.004, 9.411) 0.812 
4 months -3.449 (-14.772, 7.874) 0.550 
8 months -5.454 (-17.888, 6.980) 0.390 
12 months -2.219 (-16.751, 12.314) 0.765 
ALSSQOL 
1 month -3.430 (-13.291, 6.432) 0.495 
4 months -1.541 (-11.866, 8.783) 0.770 
8 months -9.702 (-20.880, 1.475) 0.089 
12 months -1.747 (14.197, 10.703) 0.783 
Caregiver Burden Inventory 
1 month 0.066 (-2.043, 2.176) 0.951 
4 months 1.209 (-0.964, 3.383) 0.275 
8 months 0.794 (-1.547, 3.134) 0.506 
12 months 1.418 (-1.228, 4.065) 0.293 
The mean values are change from baseline through 1 year of follow-up per 120 g units. 
ALSFRS-R, revised Amyotrophic lateral sclerosis functional rating scale; ALSSQOL, Amyotrophic 
Lateral Sclerosis Specific Quality of Life; CI, confidence interval. 
Supplementary Methods 
Outcome measures 
ALSFRS-R is an ordinal rating scale (ratings 0 to 4) used to determine subjects' 
assessment of their capability and independence in 12 functional activities.1 All 12 
activities are relevant in ALS. Forty-eight is the highest number possible, and reflects 
the score of people in the normal healthy population. The vital capacity (VC) (percent 
of predicted normal) was determined, using the upright slow VC method. HHD 
(hand-held dynamometry) is a non-invasive device that allows measurements of 
isometric strength in muscle groups of the arms and legs. The ALSSQOL was 
developed to reflect overall QOL rather than health-related QOL and is based on the 
McGill Quality of Life Questionnaire. The ALSSQOL has a total of 46 items (ratings 1 
to 10) that can be divided into six factors.2 The higher the total number, the better the 
QOL. The CBI is a 24-item multi-dimensional questionnaire measuring caregiver 
burden.3 Scores for each item are evaluated from 0 (not at all disruptive) to 4 (very 
disruptive). A total score >36 indicates a risk of “burning out,” whereas scores near or 
slightly above 24 indicate a need to seek some form of respite care. 
 
Model selection 
In the primary analysis, ALSFRS-R scores were analysed for all patients in the 
intention-to-treat population by use of a random slopes regression model: 
 
   Yij=B1trti+B2trtitimeij+b0i+b1itimeij 
 
Where Y is the ALSFRS-R score, i denotes a particular patient, j indicates time. trt 
indicates whether the patient received ceftriaxone (trti=1) or placebo (trti=0). The model 
had two fixed effect components (B1, B2) for each patient, with random effects (b0i, b1i). 
In our post-hoc total drug exposure analysis, ALSFRS-R scores were also analysed 
by use of a random slopes regression model4:  
 
Yij=B1trti+B2trtitotal drug exposureij+B3baseline ALSFRS-R+B4age+B5disease 
duration+B6sex+B7riluzole+B8El Escorial criteria+b0i+b1itimeij 
 
Total drug exposure of both ceftriaxone and placebo was substituted for time, because 
total drug exposure is a time-dependent variable that positively correlates with time. 
The model had eight fixed effect components (B1, B2…B8) for each patient, with 
random effects (b0i, b1i). The effect of death filter was considered negligible because the 
observation period is 1 year at most, and to differentiate death filter and random dropout 
is not practical. As the t1/2 of ceftriaxone is less than 12 hours, the onset of ceftriaxone 
action was considered to be at the same time of ceftriaxone administration. Interaction 
terms between time and other covariates (baseline ALSFRS-R, disease duration, etc.) 
were not considered, so that we could directly compare results of our model with those 
of the primary analysis. Higher order dose effects were also not considered for the same 
reason. 
 
1. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS 
functional rating scale that incorporates assessments of respiratory function. BDNF 
ALS Study Group (Phase III). J Neurol Sci 1999;169:13-21. 
2. Simmons Z, Felgoise SH, Bremer BA, et al. The ALSSQOL: balancing physical 
and nonphysical factors in assessing quality of life in ALS. Neurology 
2006;67:1659-64. 
3. Novak M, Guest C. Application of a multidimensional caregiver burden inventory. 
The Gerontologist 1989;29:798-803 
4. Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyse 
unbalanced repeated measures and longitudinal data. Stat Med 1997;16:2349-80. 
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Abstract  
Difficulty swallowing (dysphagia) is a major symptom of neuromuscular diseases, and 
often leads to life-threatening events such as aspiration pneumonia and suffocation. 
Although bulbar dysfunction is an important prognostic factor, reliable outcome measures 
have not been fully established to evaluate dysphagia in neuromuscular diseases. Spinal 
and bulbar muscular atrophy (Kennedy’s disease) is a neuromuscular disease 
characterized by weakness of limb, facial, and oropharyngeal muscles. Patients have 
expanded CAG repeats in the androgen receptor gene. We aimed to clarify the 
characteristics of dysphagia in spinal and bulbar muscular atrophy using a 
videofluoroscopic swallowing study and to identify the plausibility of videofluoroscopic 
outcome measures for quantitative analysis. 
A videofluoroscopic swallowing study was performed on 111 consecutive genetically 
confirmed patients with spinal and bulbar muscular atrophy and 53 age- and sex-matched 
healthy controls. Swallowing of 3 mL liquid barium was viewed in the lateral plane and 
was analysed by two independent evaluators using Logemann’s videofluorographic 
examination of swallowing worksheet. We investigated which videofluoroscopic findings 
are critical to differentiate patients and controls, and between patients with and without 
subjective dysphagia. 
Of more than 40 radiographic symptoms, the most pertinent abnormal findings in patients 
with spinal and bulbar muscular atrophy included Vallecular residue after swallow 
(residue just behind the tongue base), Nasal penetration, and Insufficient tongue 
movement (P < 0.001 for each) compared with healthy controls. Quantitative analyses 
showed Pharyngeal residue after initial swallowing, Oral residue after initial swallowing, 
Banno et al.   4 
Multiple swallowing sessions, and Penetration–aspiration scale were significantly worse 
in patients (P ≤ 0.005 for each) compared with controls. In patients with spinal and bulbar 
muscular atrophy, laryngeal penetration was observed more frequently in patients without 
subjective dysphagia. Quantitative measures corresponded well with qualitative 
abnormalities but had limitations in reproducibility. 
The qualitative and quantitative analyses of 111 patients showed that dysphagia of spinal 
and bulbar muscular atrophy is characterized by impaired tongue movement in the oral 
phase and nasal penetration followed by pharyngeal residues, which resulted in multiple 
swallowing sessions and laryngeal penetration.  Given that the reproducibility and 
validity of videofluoroscopic data were partly compensated using the average values of 
three consecutive 3-mL barium swallows in our ad hoc reproducibility study, Pharyngeal 
residue after initial swallowing and Penetration-aspiration scale could be potential 
outcome measures in clinical trials. All patients, including those without subjective 
dysarthria, would be advised to practice the chin-tuck maneuver and the effortful swallow 
to reduce pharyngeal residues and penetration risk. 
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Introduction 
The nervous system precisely controls the swallowing function in humans. Many 
neurological diseases give rise to difficulty swallowing (dysphagia) and aspiration 
pneumonia, which directly impact a given patient’s prognosis. Since neurological 
diseases vary by affected nervous systems, each disease has a different mechanism and 
clinical phenotype of dysphagia.  To date, dysphagia caused by some neurological 
diseases such as Parkinson’s disease, Guillain–Barré syndrome, multiple sclerosis, and 
cerebrovascular diseases can be partially treated by medication and rehabilitation. 
Effective interventions, however, for dysphagia are scarce and are highly sought after for 
neuromuscular diseases, especially motor neuron diseases. 
    Spinal and bulbar muscular atrophy (SBMA), also known as Kennedy’s disease, is a 
neuromuscular disease with extensive loss of lower motor neurons characterized by 
muscle atrophy, weakness, dysarthria, and dysphagia (Kennedy et al., 1968; Sperfeld et 
al., 2002; Sobue et al., 2011). SBMA exclusively affects males in their thirties or forties 
and the disease progression is slow. Early manifestations are typically hand tremor and 
muscle weakness. Approximately 5 years after initial signs of muscle weakness, affected 
patients require the use of a handrail for stairs and also dysarthria develops. Dysphagia 
develops in these patients after about 10 years of muscle weakness, followed by the need 
to use a cane and a wheelchair (Atsuta et al., 2006). The main cause of death in patients 
with SBMA is pneumonia due to bulbar palsy; dysphagia due to bulbar palsy is an 
important prognostic factor for SBMA. 
    The molecular basis of SBMA is the expansion of a trinucleotide CAG repeat, which 
encodes a polyglutamine tract, in the androgen receptor gene (La Spada et al., 1991). 
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Several studies have shown that CAG repeat size correlates with the age of onset in 
polyglutamine diseases, including SBMA (Atsuta et al., 2006; Hashizume et al., 2012). 
In SBMA, autopsy findings have shown that lower motor neurons were markedly 
depleted through all spinal segments, and neurons in the hypoglossal, facial, and 
trigeminal motor nuclei were severely depleted or atrophic (Sobue et al., 1989). 
Immunohistological staining shows abnormal protein deposits in the nuclei of remaining 
neurons, which were caused by lengthened CAG repeats (Adachi et al., 2005; Banno et 
al., 2012). Androgen deprivation therapy using an LH-RH agonist, leuroprorelin, 
decreases abnormal protein deposits and attenuates neurodegeneration in transgenic mice 
model of SBMA (Katsuno et al., 2003). The potential effect of this therapy has also been 
suggested in clinical trials (Banno et al., 2009; Katsuno et al., 2010). 
    Clinical markers reflecting disease processes are necessary for the design of clinical 
trials in neurological diseases as endpoints. Despite the importance of the swallowing 
function in patients’ prognosis, reliable clinical markers to assess dysphagia have not 
been established. To investigate dysphagia in SBMA patients has several advantages. 
First, the disease mechanism is known to be a single cause, CAG repeat expansion, which 
would be ideal for accurate diagnosis and associated with less phenotypic heterogeneity 
than other neurological disorders such as amyotrophic lateral sclerosis (ALS). Second, 
most patients with SBMA are without apparent cognitive dysfunction leading to 
pseudobulbar palsy. Third, topographical simplicity of affected neurons merits 
understanding the characteristics and pathophysiology of dysphagia. Here, we 
investigated the findings of a videofluoroscopic swallowing study (VFSS) in patients 
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with SBMA to clarify the mechanism of dysphagia and to identify the plausibility of 
VFSS-based outcome measures for quantitative analysis. 
 
Materials and methods  
Participants 
All the participating patients with SBMA and the healthy control participants underwent 
VFSS at Nagoya University Hospital from August 2003 to September 2010. VFSS 
reading was performed from November 2009 to February 2011. We also evaluated the 
backgrounds of the participants and their motor functions (CAG repeat length, ALSFRS-
R etc.) at the time of the VFSS. None of the SBMA participants had had leuprorelin 
acetate for the treatment of dysphagia at the time of the VFSS. None of the control 
participants had any medical history of dysphagia or dysphagia-related diseases. All 
participants with SBMA gave their written informed consent for the genetic analyses.  
 
Videofluoroscopic swallowing study (VFSS) 
In the VFSS, participants were instructed to swallow 3 mL of 40% w/v barium sulphate 
twice in a standing position, as viewed in the lateral plane. To eliminate unnecessary 
irradiation exposure, the irradiation area was confined to the oral, pharyngeal, laryngeal, 
and upper esophageal areas for all participants. Each swallowing was recorded and 
included at least 20 seconds after the initial swallow. VFSS data were recorded on 
MiniDV digital videotape (Sony, Japan) at 30 frames per second. We analysed 
quantitative and qualitative findings on VFSS in consecutive patients with SBMA and 
healthy age- and sex-matched controls. All parameters were measured by two 
Banno et al.   8 
independent evaluators (MD and SLP), who were blinded to details of the participants’ 
backgrounds according to the standard procedures (Logemann et al., 1989; Logemann et 
al., 2000). 
    Qualitative and quantitative findings from the swallowing examination were measured 
using Logemann’s videofluorographic examination of swallowing worksheet which 
contains more than 40 qualitative and quantitative radiographic symptoms. The two 
evaluators discussed and agreed on the details of the definitions before the measurement 
in accordance with the definition of each symptom, as described previously (Logemann, 
1998).  
 
Qualitative analyses 
Qualitative items consisted of 6 items in the preparation to swallow; 15 items in the oral 
phase; 15 items in the pharyngeal phase; and 3 items in the cervical esophageal phase 
(Supplementary Table 1). The radiographic symptoms were read by the two evaluators 
independently and any discrepancies between the two evaluators were discussed later and 
found to be the same findings. If there was more than one positive radiographic symptom 
in two 3-ml-swallowings, then the swallowing test was considered positive for qualitative 
analyses. 
 
Quantitative analyses 
For quantitative analyses, the oral and pharyngeal residues were measured using semi-
quantitative scales: 0, 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100%. Quantitative oral 
and pharyngeal barium residues were measured solely by the first 3 mL swallowed 
Banno et al.   9 
because the first residue directly affects the second one. To assure intra- and inter-rater 
reliabilities, we trained the evaluators for this method. The concordance rates of 
quantitative measurements by two evaluators in the middle of, and again after, the study 
were 0.95, and 0.90, respectively. Given that piecemeal deglutition, a VFSS finding of 
multiple repeated swallows to empty a bolus from the oral cavity, is often observed in 
patients with SBMA, we measured pharyngeal residues after initial swallowing as well as 
those after piecemeal deglutition. We also measured times (sessions) of piecemeal 
deglutition for the first 3-mL barium swallow. Temporal measurements were evaluated as 
follows. The stage transition duration (STD), also known as pharyngeal delay time, was 
defined as the interval from the bolus passing the base of the tongue to the onset of 
laryngeal elevation, whereas the duration of maximum laryngeal elevation (laryngeal 
elevation duration; LED) was the length of time during which the larynx was maximally 
elevated from its rest position. The duration of cricopharyngeal opening (DCPO), also 
known as the duration of opening of the upper esophageal sphincter (DOOUES or 
DOUES), was defined as the length of time during which the cricopharyngeal sphincter 
was open. The duration of oral transit duration (OTD) was defined as the length of time 
from initiation of the posterior bolus movement in the oral cavity to arrival of the bolus at 
the ramus of the mandible. The pharyngeal transit duration (PTD) was defined as the 
length of time from the arrival of the head of the bolus at the ramus of the mandible to the 
tail of the bolus through the upper esophageal sphincter (Priefer and Robbins, 1997). The 
mean values of the first and the second doses of barium sulphate (3 ml) were calculated 
for all the temporal parameters of the VFSS. For the first swallow, the value of 
oropharyngeal swallowing efficiency (OPSE) was calculated as the percentage of the 
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bolus swallowed into the esophagus divided by the oropharyngeal transit time (OTD + 
PTD). OPSE is a summary measure of swallow function because it has been found to 
correlate with the degree of impairment in five patient populations including patients with 
oropharyngeal cancer, laryngeal cancer, and stroke (Rademaker et al., 1994).   
 
Penetration-aspiration scale 
For aspiration and penetration findings, we used a penetration-aspiration scale, an 8-point 
scale to describe penetration and aspiration events. Scores are determined primarily by 
the depth to which material passes into the airway and by whether or not material 
entering the airway is expelled (Score 8 being the worst aspiration). Acceptable intra- and 
inter-rater reliability for the scale has been established, with sufficient validity to support 
its introduction into clinical practice (Rosenbek et al., 1996). 
 
Functional severity score 
At the time appointed for the VFSS, we also administered the revised amyotrophic lateral 
sclerosis functional rating scale (ALSFRS-R). The ALSFRS is a validated questionnaire-
based scale that measures physical function in patients with amyotrophic lateral sclerosis 
performing activity of daily living (The ALS CNTF treatment study (ACTS) phase I-II 
Study Group, 1996). The revised version of the ALSFRS was designed to improve the 
disproportion of weighting to the limbs and bulbar system as compared with respiratory 
dysfunction (Cedarbaum, 1999). The ALSFRS-R was translated into the Japanese 
language and validated (Ohashi et al., 2001). 
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    The ALSFRS-R consists of 12 items: speech, salivation, swallowing, handwriting, 
cutting food and handling utensils, dressing and hygiene, turning in bed and adjusting bed 
clothes, walking, climbing stairs, dyspnoea, orthopnoea, and respiratory insufficiency. 
We used the total score and the sum of three bulbar-related subscores (speech, salivation, 
and swallowing) for analysis. The swallowing subscore was used to judge the presence of 
the patient’s subjective dysphagia. We defined overt subjective dysphagia as a score of 
less than 4 (normal eating habits) on the swallowing subscore of the ALSFRS-R. 
 
Genetic analysis 
We extracted genomic DNA from peripheral blood of the SBMA patients using 
conventional techniques. We carried out PCR amplification of the CAG repeat in the 
androgen receptor gene using a fluorescent-labeled forward primer (5’-
TCCAGAATCTGTTCCAGAGGTGC-3’) and a non-labeled reverse primer (5’-
TGGCCTCGCTCAGGATGTCTTTAAG-3’). The details of the PCR conditions have 
been described previously (Doyu et al., 1992). Aliquots of the PCR products were 
combined with loading dye and separated by electrophoresis using an autoread sequencer 
(SQ-5500; Hitachi Electronics Engineering). The size of the PCR standards was 
determined by direct sequencing, as described previously (Doyu et al., 1992). 
 
Statistics 
Statistical analyses were performed with IBM SPSS Statistics, version 19 (IBM Japan). 
Descriptive variables such as the mean, standard deviation, and range were used to 
summarize the quantitative measures. For qualitative analyses, we used chi-square to find 
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the differences between SBMA patients and controls, and between the subjective 
dysphagia group and the group without subjective dysphagia. For quantitative measures, 
we analysed the data by Spearman’s rank correlation and Student’s t test. We considered 
P values less than 0.05 as significant and correlation coefficients R greater than 0.3 as 
strong. For the analysis of relationships between subjective dysphagia and penetration, 
the McNemar test was performed (Table 5). 
 
Ethics 
This study was conducted according to the Declaration of Helsinki and its amendments. 
Written informed consent was obtained from each participant. Participants were free to 
withdraw from the study at any time for any reason. The Ethics Committee of Nagoya 
University Graduate School of Medicine approved the study. Confidentiality was ensured 
by assigning a study code to each participant. All studies conformed to the ethical 
guidelines for human genome/gene analysis research and the ethical guidelines for 
clinical research endorsed by the Japanese government. 
 
Ad hoc study 
To evaluate the reproducibility and validity of the VFSS measurement for barium 
residues, consecutive patients with SBMA were enrolled in an ad hoc study from May 
2010 to August 2010. All participants in this ad hoc study (n = 20) were also evaluated in 
our previously described main study (n = 111). Participants underwent a VFSS twice 
during a month. The first and second VFSS were conducted on different dates at intervals 
of 7 to 30 days. In the VFSS of the ad hoc study, the participants were instructed to 
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swallow 3 mL of 40% w/v barium sulphate three times and 10 mL barium sulphate once. 
To avoid unfavourable carryover of residues to the next barium swallows, participants 
were instructed to conduct 10 mL water swallowing once and saliva swallowing twice, 
after each swallowing of barium. Pharyngeal barium residue and times of piecemeal 
deglutition (multiple repeated swallows) were measured blindly by two independent 
evaluators (MD and SLP), according to the standard procedures described previously.  
    To evaluate the validity of the measurement, the modified Norris scale (Limb Norris 
score and Norris bulbar score), SBMA functional rating scale (SBMAFRS), SWAL-QOL 
symptom subscores, and Swallowing Disturbance Questionnaire-Japanese (SDQ-J) were 
conducted. The modified Norris scale is a rating scale for ALS, which consists of two 
parts: the Limb Norris score and the Norris bulbar score. The former has 21 items to 
evaluate limb function and the latter has 13 items to assess bulbar function. Each item is 
rated in four ordinal categories, and thus the best scores possible are 63 and 39, 
respectively.  The original version has been translated into Japanese and validated (Oda et 
al., 1996). SBMAFRS is a validated 14-item severity score for SBMA patients, which 
focuses on swallowing dysfunction instead of respiratory dysfunction (as in the ALSFRS-
R) (Hashizume et al., 2015). The best possible score is 56 and the worst possible score is 
0. The SWAL-QOL is a 44-item questionnaire about the impact of swallowing on quality 
of life. We used the data of 14 symptom items from the scale focusing on subjective 
dysphagia for the present study (McHorney et al., 2002). The best possible score is 70 
and the worst possible score is 0. The SWAL-QOL has been translated into Japanese and 
validated (Wada et al., 2003). The SDQ is another questionnaire used to evaluate 
swallowing function (Manor et al., 2007). The best possible score is 0.5 and the worst 
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possible score is 44.5. The SDQ was translated into Japanese and validated as the SDQ-J 
(Yamamoto et al., 2012). The SDQ-J is divided into three domains: oral deficits, 
pharyngeal deficits, and history of pneumonia. We analysed the data by intraclass 
correlation (1, 1) for reproducibility and Spearman’s rank correlation for validity.  
 
 
Results 
A total of 111 SBMA patients (53.2 ± 10.4 years of age; range 27-81) and 53 healthy 
controls (50.8 ± 9.0 years of age; range 40-71) were included in the study (Table 1). All 
participants were Japanese males. The SBMA group and the control group were similar 
in age (P = 0.16). The characteristics of this study population, such as age, CAG repeat 
length, disease duration and ALSFRS-R scores, were similar to those of previous studies 
(Atsuta et al., 2006; Katsuno et al., 2010; Fernández-Rhodes et al., 2011; Hashizume et 
al., 2012). Fifty-three out of 111 of the SBMA group reported having subjective 
dysphagia as determined by the ALSFRS-R swallowing subscore. Patients with 
subjective dysphagia were significantly older, with later disease-onset, lower total 
ALSFRS-R score, and lower ALSFRS-R bulbar subscores (Table 1). On the contrary, 
CAG repeat length and disease duration were not statistically different between the 
subjective dysphagia group and those without subjective dysphagia. 
 
Qualitative analyses  
SBMA vs. control 
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We compared qualitative radiographic symptoms (findings) in patients in the SBMA 
group with those in the control group. Significant qualitative characteristics of VFSS 
findings in the SBMA group were: Vallecular residue after swallow (residue just behind 
the tongue base), Residue (stasis) in both pyriform sinuses (residue in both sides of the 
laryngeal orifice), Piecemeal deglutition (multiple sessions of swallowing), Poor 
epiglottic inversion, Residue (stasis) on tongue, Nasal penetration, Reduced anterior-
posterior tongue movement, Reduced laryngeal closure, Residue throughout the pharynx, 
Coating on pharyngeal walls after swallow, Repetitive lingual rolling actions, Head 
backward tilt in swallowing, Residue at top of airway, and Head forward tilt in 
swallowing (all were P < 0.05; Fig. 1, bold radiographic symptoms).  More than 80% of 
patients in the SBMA group showed Vallecular residue after swallow (residue just 
behind the tongue base). Uncontrolled bolus/ premature swallow, Residue (stasis) in both 
pyriform sinuses (residue in both sides of the laryngeal orifice), and Piecemeal 
deglutition (multiple sessions of swallowing) were noted in about 50% of the SBMA 
group. Ten out of 14 significantly abnormal findings seen in patients with SBMA were 
the pharyngeal phase radiographic symptoms. 
 
SBMA with subjective dysphagia vs. without subjective dysphagia 
Among the characteristic qualitative radiographic symptoms (findings) described above, 
several findings significantly more frequently found in patients with subjective dysphagia 
compared with those without subjective dysphagia: Residue (stasis) in both pyriform 
sinuses (residue in both sides of the laryngeal orifice), Piecemeal deglutition (multiple 
sessions of swallowing), Poor epiglottic inversion, Residue (stasis) on tongue, Nasal 
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penetration, Reduced anterior-posterior tongue movement, Residue throughout the 
pharynx, and Repetitive lingual rolling actions (All were P < 0.05; Fig. 2, bold 
radiographic symptoms). Half of the findings that differentiated the patients with and 
without subjective dysphagia were oral phase radiographic symptoms.  
 
Clinical background and radiographic symptoms 
Of the qualitative radiographic symptoms, 14 that were characteristic of SBMA 
participants were associated with older age, later disease-onset, lower total ALSFRS-R 
scores, and lower ALSFRS-R bulbar subscores, although laryngeal penetration-related 
findings (Reduced laryngeal closure, Residue at top of airway) were not strongly 
correlated with ALSFRS-R bulbar subscores (P = 0.6, P = 0.11 respectively; 
Supplementary Table 2). CAG repeat length and disease duration were irrelevant to 
VFSS qualitative radiographic symptoms.  
 
Quantitative analyses 
SBMA vs. control 
Compared with participants in the control group, patients with SBMA had a significantly 
greater amount of Pharyngeal residue after initial swallowing (mean ± SD: control 6.6 ± 
10.8%, SBMA 14.0  ± 18.2%, P = 0.001), more Oral residue after initial swallowing 
(control 3.8 ± 2.9%, SBMA 5.2  ± 4.7%, P = 0.005), more frequent Piecemeal deglutition 
(multiple sessions of swallowing) (control 1.2 ± 0.4 times, SBMA 1.5  ± 0.8 times, P < 
0.001) and higher score on the Penetration-aspiration scale (control 1.1 ± 0.3, SBMA 1.4  
± 0.8, P = 0.003) (Table 2).  On the contrary, Pharyngeal residue after piecemeal 
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deglutition, Oral residue after piecemeal deglutition, Oro-pharyngeal swallowing 
efficiency (OPSE) and all the time-related measures did not reflect any significant 
difference between participants in the control group and those in the SBMA group (Table 
2). 
 
SBMA with subjective dysphagia vs. without subjective dysphagia 
Among the four significant quantitative parameters that were characteristic of SBMA, 
patients with subjective dysphagia showed a significantly greater amount of Oral residue 
after initial swallowing (subjective dysphagia group 6.7 ± 5.6%, group without subjective 
dysphagia 3.9  ± 3.3%, P = 0.002) and more frequent Piecemeal deglutition (subjective 
dysphagia group 1.7 ± 0.8, group without subjective dysphagia 1.2 ± 0.6%, P = 0.001) 
(Table 3). Both Oral residue after initial swallowing and Piecemeal deglutition are 
classified as oral and voluntary measures. In contrast, Pharyngeal residue after initial 
swallowing and Penetration–aspiration scale, classified as pharyngeal and involuntary 
measures, did not show any significant difference between the group with subjective 
dysphagia and those without.  
    These two oral quantitative parameters (Oral residue after initial swallowing and 
Piecemeal deglutition) correlated fairly well with ALSFRS-R bulbar subscores (R = -0.39 
and -0.35, respectively), whereas Pharyngeal residue after initial swallowing and 
Penetration-aspiration scale, which suggest pharyngeal phase dysfunction (R = -0.29 and 
-0.18), did not (Table 4). 
 
Laryngeal penetration 
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Penetration-aspiration scale results revealed no aspiration episodes in our study. 
However, out of the 111 patients with SBMA, laryngeal penetration was found in 29 
participants (26%). Patients with laryngeal penetration showed older age and older 
disease onset, but ALSFRS-R total score and ALSFRS-R bulbar subscores were not 
different between patients with and without laryngeal penetration (P = 0.81, 0.60, 
respectively) (Supplementary Table 3). 
    Although not statistically significant, the Penetration-aspiration scale results tended to 
be higher in patients with SBMA who had no subjective dysphagia (Table 3). 
Counterintuitively, laryngeal penetration was noted more often in patients without 
subjective dysphagia (19/58 cases, 33%) than in patients with subjective dysphagia 
(10/53 cases, 19%), and this difference was statistically significant (P < 0.001) (Table 5). 
 
Ad hoc study for reproducibility and validity of pharyngeal residues 
A total of 20 consecutive SBMA patients (58.8 ± 12.0 years of age) were included in the 
ad hoc study (Supplementary Tables 4, 5). Reproducibility of pharyngeal residues was 
more favorable in the mean of three swallows than in the first swallows (3mL and 10 mL) 
assessed by intraclass correlation (Supplementary Table 6). External validity was 
evaluated by comparing quantitative videofluoroscopic measurements with various 
swallowing severity scores (ALSFRS-R bulbar subscores, SBMAFRS bulbar subscores, 
SWAL-QOL, SDQ-J). Compared with single swallows, better correlation coefficients 
were noted between pharyngeal residue after initial swallowing (the mean of three 
swallows) and swallowing-related severity scores, especially SDQ-J (Supplementary 
Table 7, upper table). No remarkable differences were found between the 3-mL barium 
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swallow and the 10-mL barium swallow in terms of external validity of pharyngeal 
residues (Supplementary Table 7). 
 
 
Discussion 
This study examined characteristics of dysphagia in 111 patients with SBMA as 
compared with 53 healthy control participants with the use of the VFSS. SBMA patients 
showed various pharyngeal and oral deficits in VFSS, in comparison with healthy 
controls. Of note, ALSFRS-R bulbar scores correlated with oral dysfunctions, but not 
with bolus penetration into the airway, in the SBMA group. Laryngeal penetration was 
significantly more frequent in the patients without subjective dysphagia.  
 
Mechanism of dysphagia in SBMA 
This study identified characteristic radiographic symptoms in the SBMA group as 
compared with the control group. These radiographic symptoms include: Vallecular 
residue after swallow (residue just behind the tongue base), Residue (stasis) in both 
pyriform sinuses (residue in both sides of the laryngeal orifice), Piecemeal deglutition 
(multiple swallowing sessions), poor epiglottic inversion, Residue (stasis) on tongue, and 
Nasal penetration. These findings were found in more than 40% of the SBMA patients 
and more frequently observed than in control participants. Other less frequent but 
statistically significant findings were related to tongue movement dysfunction, 
pharyngeal residue, and bolus penetration into the airway. 
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    Taken together, we speculate that the mechanisms of dysphagia in SBMA patients 
function as follows (Fig. 3). Dysphagia in SBMA stems from both Dysfunctional tongue 
movement and Incomplete velar elevation/tongue atrophy. Dysfunctional tongue 
movement leads to oral and pharyngeal residues, both of which eventually result in 
multiple swallowing sessions (Piecemeal deglutition) and Laryngeal penetration.  
Incomplete velar elevation and tongue atrophy lead to Nasal penetration, inevitably 
causing low pharyngeal pressure, which leads to pharyngeal residue (Residue in vallecula 
and pyriform sinuses), Poor epiglottic inversion/Reduced laryngeal closure, and finally 
Laryngeal penetration. Laryngeal penetration is defined as entry of material into the 
laryngeal vestibule but not below the true vocal folds (Robbins et al., 1992). Penetrations 
were reported to be significantly more frequent after 50 years of age in normal aging.  For 
people younger than 50, 7.4% of swallows exhibited penetration, while for people 50 
years of age and over, 16.8% of swallows showed penetration in the healthy population 
(Daggett et al., 2006). Despite the fact that laryngeal penetration can be seen in the 
healthy controls, participants without laryngeal penetration were reported to have the 
lowest risk of developing pneumonia. Furthermore, patients with laryngeal penetration, 
tracheobronchial aspiration, or silent tracheobronchial aspiration were, in increasing order 
of magnitude, significantly more likely to develop pneumonia than patients with normal 
swallowing (Pikus et al., 2003).  
    A previous report using fiberoptic endoscopy also found that patients with SBMA have 
pharyngeal residues (Warnecke et al., 2009). Using VFSS findings, our study supports 
these findings and further found potential mechanisms of dysphagia and aspiration in 
SBMA patients.  
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Clinical outcome measure  
One of the goals of this study was to find reliable objective quantitative markers that 
reflect severity of bulbar palsy in motor neuron disease patients. Clinical biomarkers are 
important to make go or no-go decisions in clinical trials.  In this SBMA patient cohort, 
we speculated that there was less burden of genetic and phenotypic heterogeneity than in 
an ALS patient cohort, which is one of the main hindrances to therapeutic development in 
motor neuron diseases.  SBMA is a slowly progressive disease (Kennedy et al., 1968; 
Hashizume et al., 2012). Thus, long-term clinical trials are necessary to assess whether 
certain drugs can alter the natural disease progression or not by targeting clinical 
endpoints such as occurrence of aspiration pneumonia or becoming wheelchair-bound. 
Suitable surrogate endpoints, which reflect the pathogenesis and severity of SBMA, are 
substantial to assess the therapeutic efficacy in drug trials.  
We previously reported tongue pressure could serve as a marker of swallowing 
function at an early stage of the disease (Mano et al., 2014). VFSS is particularly useful 
in characterizing dysphagia mechanisms because it allows visualization of the 
swallowing movement while tongue pressure assesses a part of the swallowing function. 
In this study, compared with controls, SBMA patients had significantly more Pharyngeal 
residue after initial swallowing, Oral residue after initial swallowing, Piecemeal 
deglutition (multiple swallowing sessions), and worse Penetration–aspiration scale 
results. Oral residue after initial swallowing and Piecemeal deglutition correlated well to 
subjective dysphagia in SBMA patients, which was essentially irrelevant to laryngeal 
penetration. At this point in our current study results, Pharyngeal residue after initial 
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swallowing and Penetration-aspiration scale could be candidates for outcome measure, 
even though longitudinal changes with the disease course of these measures should be 
clarified in the future and a ceiling effect of the penetration-aspiration scale has been 
reported (Ludlow et al., 2007).  
    Pharyngeal barium residue has also been shown to correlate with the incidence of 
aspiration and quantitative scintigraphy data, suggesting that this measurement is a 
reliable tool to evaluate swallowing function in patients with neuromuscular disorders 
(Eisenhuber et al., 2002; Logemann et al., 2005). Pharyngeal residue has also been 
reported to be the most important VFSS variable in reflecting pharyngeal pressure 
measurements in both diseases and healthy participants (Pauloski et al., 2009). To 
measure pharyngeal residue more precisely, the Normalized Residue Ratio Scale, using 
image analysis software, was recently proposed (Pearson et al., 2013). Previous studies 
have shown high intra- and inter-rater reliabilities (Kuhlemeier et al., 1998), although not 
much is known about the reproducibility of this parameter. To improve the shortcomings, 
we also evaluated the reproducibility and validity of pharyngeal barium residues and 
piecemeal deglutition. The results showed better reproducibility and validity in the 
average values of three consecutive 3-mL barium swallows. 
We also evaluated temporal parameters, which did not reveal significant importance 
in reflecting dysphagia severity in this cohort.  Historically, cricopharyngeal myotomy in 
patients with ALS who have upper esophageal sphincter spasms has been reported (Mills., 
1973; Lebo et al., 1976; Loizou et al., 1980). But most ALS patients were reported to 
maintain normal upper esophageal sphincter relaxation (Higo et al., 2002).  In our study, 
a longer duration of cricopharyngeal opening (DCPO), in other words a longer upper 
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esophageal sphincter opening duration, was related to smaller amount of pharyngeal and 
oral residues in healthy controls, whereas comparable relationships were not found in the 
SBMA group (data not shown). Variance of compensatory mechanisms in SBMA 
patients may have contributed to the lack of relationships between pharyngeal residues 
and DCPO in SBMA, and also the lack of significant difference in DCPO between the 
SBMA group and control.  
 
Strengths and limitations 
VFSS is a direct investigational method to delineate both spatial and temporal 
characteristics of swallowing in a patient. In the present study, SBMA patients with 
subjective dysphagia had both qualitative and quantitative oral-phase VFSS abnormalities. 
We also found that risk of laryngeal penetration is not relevant to subjective dysphagia or 
ALSFRS-R scores in the SBMA group. Possibly, this paradoxical finding can be 
explained by the speculation that patients with subjective dysphagia tend to swallow 
carefully (slowly or with multiple sessions of swallowing), leading to low incidence of 
laryngeal penetration. To assess the severity of dysphagia, VFSS is a superior method in 
terms of visibility of dysphagia mechanism, penetration, and aspiration among several 
modalities. VFSS is also useful to evaluate the effect of adaptive methods like the chin-
tuck maneuver, the supraglottic swallow, and the effortful swallow. Given that the 
pharyngeal residue is the most common finding in SBMA patients and penetration risk 
exists even in those without subjective dysphagia, we would recommend the chin-tuck 
maneuver and the effortful swallow as a safe method of swallowing for all the SBMA 
patients with dysphagia (Wheeler-Hegland et al., 2009; Leigh et al., 2015). We recently 
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reported that a 6-week head lift exercise may improve swallowing dysfunction as 
measured by tongue pressure (Mano et al. 2015). Reinforcement of compensatory 
swallowing mechanisms may lead to effective rehabilitation in dysphagia patients.   
   Limitations of VFSS include poor reproducibility and radiation exposure. Longitudinal 
change in VFSS findings, especially in pharyngeal residue in SBMA patients, is another 
major limitation (Hashizume et al., 2012), partly caused by poor reproducibility of VFSS 
findings. Measuring multiple swallowing and using the average values of three 
swallowing may be a better method to improve poor reproducibility in VFSS, given our 
small sample-size ad hoc data. Comparisons between the control group and the diseased 
group are crucial to establish valid VFSS markers, but due to radiation problems we 
limited the number of healthy controls as compared with the number of patients with 
SBMA in our main study and in our ad hoc study. We could not analyse direct 
relationships between VFSS findings and pneumonia since only one of the participants 
had dysphagia severe enough to experience pneumonia, which was partly because our 
cohort focused on ambulatory patients. Since swallowing is composed of serial motions 
of various bulbar musculatures, multiple modalities including VFSS, tongue pressure, 
patient-reported outcomes, and other devices are necessary for dysphagia assessment in 
SBMA patients. Invention of noninvasive portable devices that can continuously measure 
pharyngeal residue would be ideal in the future. 
 
Conclusion 
Our data suggest that ALSFRS-R bulbar subscores are not relevant to bolus penetration 
into the airway. Our data indicate that VFSS of SBMA patients is qualitatively 
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characterized by oral and pharyngeal barium residue and laryngeal penetration, resulting 
from tongue and pharyngeal weakness, as well as compensative responses including 
repetitive swallows. Among quantitative indices, both Pharyngeal residue after initial 
swallowing and Penetration-aspiration scale reflect the major features of dysphagia in 
SBMA. These findings will be applied to future clinical trials of pharmacological and 
physical interventions. 
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 Figure legends 
Figure 1 Results of qualitative analyses (SBMA group vs. control group). 
We compared qualitative radiographic symptoms in SBMA patients with those in the 
control group. Significant qualitative characteristics of VFSS findings in the SBMA group 
are shown in bold. More than 80% of SBMA patients had vallecular residue after 
swallow (residue just behind the tongue base). About 50% of SBMA patients had 
uncontrolled bolus/ premature swallow, residue (stasis) in both pyriform sinuses (residue 
in both sides of the laryngeal orifice), and piecemeal deglutition (multiple swallowing 
sessions). Ten out of 14 of the findings that differentiate SBMA patients from the control 
group were pharyngeal phase radiographic symptoms. Statistical significance was 
analysed by chi-square test. 
 
Figure 2 Results of qualitative analyses of SBMA patients (with vs. without subjective 
dysphagia). 
Among SBMA-related qualitative radiographic symptoms, we compared characteristic 
findings of patients with subjective dysphagia and those of patients without subjective 
dysphagia. Significant differences between the two group (SBMA patients with and 
without subjective dysphagia) are shown in bold. Half of the findings which differentiate 
with from without subjective dysphagia group were oral phase radiographic symptoms. 
Statistical significance was analysed by chi-square test. 
 
Figure 3 Putative scheme of dysphagia in SBMA patients. 
Banno et al.   36 
Dysphagia in SBMA stems from both Tongue movement dysfunction and Incomplete velar 
elevation/tongue atrophy. Tongue movement dysfunction leads to oral and pharyngeal 
residues both of which eventually result in multiple swallowing sessions (Piecemeal 
deglutition) and Laryngeal penetration.  Incomplete velar elevation/tongue atrophy leads 
to Nasal penetration, inevitably causing low pharyngeal pressure which leads to 
pharyngeal residue (Residue in vallecula and pyriform sinuses), Poor epiglottic 
inversion/Reduced laryngeal closure and finally Laryngeal penetration.   
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Table 1 Demographics of study population at baseline 
 
Characteristic 
SBMA 
P-value 
Total SBMA 
 (n = 111) 
mean ± SD 
(range) 
With 
subjective 
dysphagia 
(n = 53) 
mean ± SD 
(range) 
Without 
subjective 
dysphagia 
(n = 58) 
mean ± SD 
(range) 
Age (years) 55.8 ± 9.8 (33-81) 
50.8 ± 10.4 
(27-74) 0.01 
53.2 ± 10.4 
(27-81) 
CAG repeat length (number) 47.9 ± 3.3
a 
(40-57) 
48.5 ± 3.5b 
(42-57) 0.39 
48.2 ± 3.4 c 
(40-57) 
Disease duration (years) 11.3 ± 8.5 (1-57) 
10.7 ± 7.5 
(1-33) 0.71 
11.0 ± 8.0 
(1-57) 
Disease onset (years) 44.5 ± 11.0 (14-66) 
40.0 ± 12.2 
(8-68) 0.05 
42.2 ± 11.8 
(8-68) 
ALSFRS-R 39.3 ± 4.1 (29-47) 
43.2 ± 3.0 
(36-48) <0.001 
41.4 ± 4.0 
(29-48) 
ALSFRS-R 
bulbar subscores 
9.7 ± 1.4 
(5-11) 
11.5 ± 0.8 
(9-12) <0.001 
10.6 ± 1.5 
(5-12) 
an = 48; bn = 56; cn = 104. 
Abbreviations: ALSFRS-R = revised amyotrophic lateral sclerosis functional rating scale. 
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Table 2 Quantitative analyses of videofluoroscopic swallowing study 
 
Characteristic 
Control 
(n = 53) 
mean ± SD 
(range) 
SBMA 
Total 
(n = 111) 
mean ± SD 
(range) 
P-value 
Pharyngeal residue 
after initial swallowing (%), 
6.6 ± 10.8 
(0-60) 
14.0 ± 18.2 
(0-75) 0.001 
Oral residue 
after initial swallowing (%) 
3.8 ± 2.9 
(0-15) 
5.2 ± 4.7 
(0-30) 0.005 
Pharyngeal residue 
after piecemeal deglutition (%) 
6.1 ± 10.6 
(0-60) 
8.0 ± 9.6 
(0-55) 0.26 
Oral residue 
after piecemeal deglutition (%) 
3.5 ± 2.8 
(0-15) 
3.9 ± 2.9 
(0-15) 0.46 
Piecemeal deglutition (times) 
(Times of multiple swallowing sessions) 
1.2 ± 0.4 
(1-2) 
1.5 ± 0.8 
(1-4) <0.001 
Oro-pharyngeal swallowing efficiency (%) 54.2 ± 17.7 (13-99) 
59.8 ± 26.6 
(4-132) 0.12 
Stage transition duration (sec) 0.34 ± 1.13 (-0.58-8.07) 
0.37 ± 0.84 
(-0.19-4.83) 0.81 
Laryngeal elevation duration (sec) 0.23 ± 0.07 (0.12-0.43) 
0.23 ± 0.10 
(0.09-0.63) 0.74 
Duration of cricopharyngeal opening (sec) 0.39 ± 0.06 (0.30-0.54) 
0.39 ± 0.07 
(0.25-0.67) 0.83 
Oral transit duration (sec) 1.03 ± 0.52 (0.30-2.70) 
0.82 ± 0.66 
(0.20-4.90) 0.47 
Pharyngeal transit duration (sec) 0.78 ± 0.19 (0.49-1.31) 
0.76 ± 0.35 
(0.48-3.13) 0.75 
Penetration-aspiration scale 1.1 ± 0.3 (1-2) 
1.4 ± 0.8 
(1-6) 0.003 
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Table 3 Quantitative analyses between patients with and without subjective dysphagia 
 
Characteristic 
SBMA 
P-value 
With 
subjective 
dysphagia 
(n = 53) 
mean ± SD 
(range) 
Without 
subjective 
dysphagia 
(n = 58) 
mean ± SD 
(range) 
Pharyngeal residue 
after initial swallowing (%) 
17.3 ± 19.0 
(0-70) 
11.0 ± 17.0 
(0-75) 0.07 
Oral residue 
after initial swallowing (%) 
6.7 ± 5.6 
(0-30) 
3.9 ± 3.3 
(0-15) 0.002 
Piecemeal deglutition (times) 
(Times of multiple swallowing 
sessions) 
1.7 ± 0.8 
(1-4) 
1.2 ± 0.6 
(1-4) 0.001 
Penetration-aspiration scale 1.3 ± 0.7 (1-5) 
1.5 ± 0.9 
(1-6) 0.22 
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Table 4 Correlation between demographics and quantitative videofluoroscopic parameters in SBMA patients (n = 111) 
 
Radiographic symptom Age (years) 
CAG repeat 
lengtha 
(number) 
Disease 
duration 
(years) 
Disease 
onset 
(years) 
ALSFRS-R 
ALSFRS-R 
bulbar 
subscores 
Pharyngeal residue 
after initial swallowing 
0.26 
P = 0.01 
0.07 
P = 0.49 
0.04 
P = 0.68 
0.25 
P = 0.009 
-0.24 
P = 0.011 
-0.29 
P = 0.002 
Oral residue 
after initial swallowing 
0.24 
P = 0.01 
-0.07 
P = 0.47 
0.04 
P = 0.67 
0.18 
P = 0.055 
-0.36 
P < 0.001 
-0.39 
P < 0.001 
Piecemeal deglutition (times)           
(Times of multiple swallowing sessions)
0.35 
P < 0.001 
-0.14 
P = 0.16 
0.06 
P = 0.52 
0.32 
P = 0.001 
-0.22 
P = 0.019 
-0.35 
P < 0.001 
Penetration-aspiration scale 0.20 P = 0.03 
-0.16 
P = 0.10 
-0.13 
P = 0.19 
0.23 
P = 0.013 
-0.04 
P = 0.65 
-0.18 
P = 0.06 
an = 104 
Abbreviations: ALSFRS-R = revised amyotrophic lateral sclerosis functional rating scale. 
Data are shown by Spearman coefficient.  
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Table 5     Relationships between subjective dysphagia and penetration 
 
 
Subjective dysphagia 
 
+ - 
Penetration 
+ 10 19 29 
- 43 39 82 
 53 58 111 
McNemar test was significant. (P < 0.001) 
 Supplementary table 1 Qualitative measurement items in videofluoroscopic findings 
 
Phase Characteristics
Preparation to swallow 
Cannot hold food in mouth anteriorly
Cannot form bolus 
Premature bolus loss 
Material falls into anterior sulcus 
Material falls into lateral sulcus 
Abnormal hold position 
Oral phase 
Delayed oral onset of swallow 
Searching tongue movements 
Tongue moves forward to start swallow 
Residue (stasis) in anterior sulcus 
Residue (stasis) in lateral sulcus 
Residue (stasis) on floor of mouth 
Residue in midtongue depression 
Residue (stasis) on tongue 
Disturbed lingual contraction 
Incomplete tongue-palate contact 
Residue on hard palate 
Reduced anterior-posterior tongue movement 
Repetitive lingual rolling actions 
Uncontrolled bolus/premature swallow 
Piecemeal deglutition
Pharyngeal phase 
Nasal penetration
Pseudoepiglottis (total laryngectomy) 
Bony outgrowth from cervical vertebrae 
Coating on pharyngeal walls after swallow 
Vallecular residue after swallow 
Coating in depression on pharyngeal wall 
Residue at top of airway 
Penetration into airway entrance 
Poor epiglottic inversion 
Reduced laryngeal closure 
Aspiration during swallow 
Residue (stasis) in both pyriform sinuses 
Residue throughout the pharynx 
Head backward tilt in swallowing 
Head forward tilt in swallowing
Cervical esophageal phase 
Esophageal-to-pharyngeal backflow  
Tracheoesophageal fistula 
Zenker’s diverticulum 
 Supplementary table 2        Demographics and qualitative videofluoroscopic findings in SBMA patients (n = 111) 
 
Radiographic symptom  
Age 
(years) 
mean ± SD
P 
CAG 
repeat 
length a 
mean ± SD
P 
Disease 
duration 
(years) 
mean ± SD
P 
Disease 
onset 
(years) 
mean ± SD
P ALSFRS-Rmean ± SD P 
ALSFRS-R
bulbar 
subscores 
mean ± SD
P 
Vallecular residue after 
swallow  
54.4 ± 10.6 <0.01 48.3 ± 3.5 0.71 11.5 ± 8.4 0.12 42.9 ± 12.5 0.03 40.9 ± 4.1 <0.01 10.5 ± 1.5 0.01 
46.9 ±  6.0 47.9 ± 3.1 8.3 ± 4.8 38.4 ± 6.4 43.8 ± 3.0 11.3 ± 1.0 
Residue (stasis) in both 
pyriform sinuses 
55.7 ± 10.3 0.01 48.2 ± 3.7 0.92 10.5 ± 6.7 0.57 45.1 ± 11.8 0.01 40.6 ± 4.4 0.05 10.3 ± 1.6 0.01 
50.8 ± 9.9 48.3 ± 3.2 11.4 ± 9.0 39.4 ± 11.2 42.1 ± 3.6 11.0 ± 1.2 
Piecemeal deglutition 56.3 ± 9.8 <0.01 47.5 ± 3.1 0.04 11.1 ± 5.5 0.87 45.2 ± 11.8 <0.01 40.4 ± 4.3 0.01 10.0 ± 1.6 <0.01 
50.3 ± 10.1 48.9 ± 3.6 10.8 ± 9.8 39.3 ± 11.2 42.3 ± 3.6 11.2 ± 1.0 
Poor epiglottic inversion 55.7 ± 9.7 0.03 48.4 ± 3.9 0.69 11.0 ± 6.6 0.99 44.7 ± 11.5 0.06 40.2 ± 4.0 0.01 10.0 ± 1.6 <0.01 
51.4 ± 10.5 48.1± 3.1 11.0 ± 8.8 40.4 ± 11.8 42.2 ± 3.9 11.1 ± 1.2 
Residue (stasis) on tongue 57.1 ± 9.3 <0.01 47.2 ± 2.8 0.01 10.8 ± 6.3 0.86 46.4 ± 11.6 0.03 39.1 ± 4.3 <0.01 10.0 ± 1.7 <0.01 
50.7 ± 10.3 48.9 ± 3.7 11.1 ± 8.9 39.5 ± 11.2 42.8 ± 3.2 11.1 ± 1.0 
Nasal penetration 55.7 ± 11.0 0.04 48.8 ± 3.7 0.18 11.3 ± 9.3 0.74 44.4 ± 12.4 0.12 40.2 ± 4.1 0.01 10.2 ± 1.6 0.02 
51.6 ± 9.7 47.9 ± 3.2 10.8 ± 7.0 40.8 ± 11.2 42.1 ± 3.9 10.9 ± 1.3 
Reduced anterior-posterior 
tongue movement 
53.4 ± 11.3 0.87 48.4 ± 2.9 0.7 12.1 ± 9.6 0.34 41.3 ± 11.6 0.59 39.0 ± 4.5 <0.01 9.8 ± 1.7 <0.01 
53.1 ± 10.0 48.2 ± 3.7 10.5 ± 7.1 42.6 ± 12.0 42.4 ± 3.4 11.0 ± 1.1 
Reduced laryngeal closure 56.2 ± 10.8 0.04 47.3 ± 4.2 0.1 9.4 ± 6.4 0.18 46.7 ± 12.9 <0.01 41.6 ± 4.0 0.73 10.5 ± 1.5 0.6 
51.8 ± 9.9 48.7 ± 3.0 11.6 ± 8.5 40.2 ± 10.7 41.3 ± 4.1 10.7 ± 1.4 
Residue throughout the 
pharynx  
57.9 ± 10.6 <0.01 47.7 ± 4.0 0.35 10.5 ± 6.7 0.73 47.3 ± 12.5 <0.01 39.4 ± 4.5 <0.01 9.7 ± 1.8 <0.01 
51.4 ± 9.8 48.4 ± 3.2 11.1 ± 8.4 40.3 ± 11.0 42.1 ± 3.6 11.0 ± 1.2 
Coating on pharyngeal walls 
after swallow  
58.9 ± 11.6 <0.01 47.6 ± 3.6 0.3 9.5 ± 4.9 0.31 49.4 ± 11.0 <0.01 40.3 ± 4.5 0.14 10.1 ± 1.7 0.09 
51.6 ± 9.5 48.4 ± 3.4 11.4 ± 8.6 40.2 ± 11.3 41.7 ± 3.9 10.8 ± 1.4 
Repetitive lingual rolling 
actions 
56.1 ± 11.3 0.16 47.8 ± 2.3 0.49 10.0 ± 5.5 0.54 46.1 ± 12.5 0.1 37.1 ± 4.4 <0.01 9.1 ± 1.7 <0.01 
52.5 ± 10.1 48.4 ± 3.7 11.2 ± 8.4 41.3 ± 11.5 42.4 ± 3.2 11.0 ± 1.1 
Head backward tilt in 
swallowing 
52.9 ± 9.6 0.9 48.3 ± 3.5 0.89 10.7 ± 6.3 0.87 42.2 ± 10.0 0.99 40.3 ± 4.4 0.18 10.0 ± 1.4 0.03 
53.2 ± 10.6 48.2 ± 3.4 11.0 ± 8.3 42.2 ± 12.2 41.6 ± 3.9 10.8 ± 1.4 
Residue at top of airway 57.3 ± 11.5 0.06 48.4 ± 3.4 0.85 9.2 ± 5.8 0.28 48.2 ± 12.6 0.01 39.6 ± 3.9 0.03 10.2 ± 1.6 0.11 
52.3 ± 10.0 48.2 ± 3.5 11.3 ± 8.3 40.9 ± 11.3 41.7 ± 4.0 10.7 ± 1.4 
Head forward tilt in 
swallowing 
55.9 ± 10.8 0.28 48.0 ± 4.2 0.8 9.4 ± 6.6 0.42 46.5 ± 12.2 0.13 39.7 ± 4.3 0.08 10.3 ± 1.6 0.38 
52.8 ± 10.3 48.3 ± 3.3 11.2 ± 8.2 41.5 ± 11.7 41.6 ± 4.0 10.7 ± 1.4 
an = 104 
Upper line denotes positive-symptom patients. Lower line denotes negative symptom patients.  
Abbreviations: ALSFRS-R = revised amyotrophic lateral sclerosis functional rating scale. 
 Supplementary table 3 Background differences between SBMA patients with and without penetration  
 
Characteristic 
SBMA 
P-value 
With penetration 
(n = 29) 
mean ± SD 
(range) 
Without penetration 
(n = 82) 
mean ± SD 
(range) 
Age (years) 56.4 ± 11.2 (28-74) 
52.0 ± 9.9 
(27-81) 0.05 
CAG repeat length (number)a 47.4 ± 4.1
b 
(42-57) 
48.5 ± 3.1c 
(40-57) 0.13 
Disease duration (years) 9.5 ± 6.7 (1-29) 
11.5 ± 8.3 
(1-57) 0.25 
Disease onset (years) 46.8 ± 12.9 (19-68) 
40.5 ± 11.0 
(8-66) 0.01 
ALSFRS-R 41.2 ± 4.0 (32-47) 
41.4 ± 4.1 
(29-48) 0.81 
ALSFRS-R 
bulbar subscores 
10.5 ± 1.6 
(7-12) 
10.7 ± 1.4 
(5-12) 0.60 
an = 104; bn= 28; cn = 76 
Abbreviations: ALSFRS-R = revised amyotrophic lateral sclerosis functional rating scale. 
 
 Supplementary table  4     Clinical features of 20 patients with SBMA (ad hoc study) 
 
 
Demographic mean ± SD (range) 
Age (years) 58.8 ± 12.0 (37-73) 
Disease onset (years) 43.5 ± 13.4 (20-66) 
Disease duration (years) 15.3 ± 8.6 (6-37) 
Total ALSFRS-R score 40.1 ± 3.6 (33-46) 
ALSFRS-R bulbar subscores 10.1 ± 1.3 (8-12) 
Limb Norris score 50.0 ± 8.5 (25-60) 
Norris bulbar score 31.9 ± 4.3 (23-38) 
SBMAFRS score 37.7±7.7 (20-50) 
SBMAFRS bulbar subscores 14.0 ± 2.8 (9-19) 
SWAL-QOL symptom subscores 51.9±9.9 (38-69) 
Total SDQ-J score 9.7±7.7 (0.5-24.5) 
SDQ-J oral score 3.3±3.0 (0-8) 
SDQ-J pharyngeal score 6.4±5.2 (0.5-18.5) 
 
Abbreviations: ALSFRS-R = revised amyotrophic lateral sclerosis functional rating scale; SBMAFRS = spinal and bulbar muscular atrophy functional rating 
scale; SWAL-QOL = a questionnaire on swallowing problems in daily life; SDQ-J = swallowing disturbance questionnaire-Japanese. 
 Supplementary table  5     Videofluoroscopic findings in ad hoc study (n = 20) 
 
 
3 mL barium 
first swallow 
mean ± SD 
(range) 
3 mL barium 
second swallow 
mean ± SD 
(range) 
3 mL barium 
third swallow 
mean ± SD 
(range) 
3 mL barium 
mean of         
three swallows
mean ± SD 
(range) 
10 mL barium 
first swallow 
mean ± SD 
(range) 
Pharyngeal residue 
after initial swallowing (%) 
11.4 ±11.0 
(2-50) 
22.3 ±24.2 
(2-90) 
17.6 ±21.7 
(2-90) 
17.1 ±17.2 
(2-65) 
18.5 ±21.5 
(1-70) 
Pharyngeal residue 
after piecemeal deglutition (%) 
8.7 ±6.3 
(2-20) 
15.6 ±15.4 
(2-50) 
11.3 ±9.3 
(2-25) 
11.9 ±9.3 
(2-30) 
6.8 ±4.9 
(0-15) 
Piecemeal deglutition (times)         
(Times of multiple swallowing sessions)
1.5 ±0.9 
(1-4) 
1.6 ±0.8 
(1-4) 
1.5 ±0.7 
(1-3) 
1.5 ±0.7 
(1-3) 
2.0 ±1.0 
(1-4) 
 
  
Supplementary table  6     Reproducibility  of  ad hoc study (n = 20) 
 
 
3 mL barium 
first swallow 
3 mL barium 
mean of three 
swallows 
10 mL barium 
first swallow 
Pharyngeal residue 
after initial swallowing (%) 
0.195 
(-0.251-0.577) 
0.729 
(0.439-0.882) 
0.882 
(0.731-0.951) 
Pharyngeal residue 
after piecemeal deglutition (%) 
0.380 
(-0.054-0.696) 
0.783 
(0.536-0.907) 
0.655 
(0.306-0.850) 
Piecemeal deglutition (times)               
(Times of multiple swallowing sessions) 
0.479 
(0.068-0.754) 
0.731 
(0.444-0.884) 
0.361 
(-0.076-0.685) 
Upper number denotes intraclass correlation (1, 1); lower number denotes 95% confidence interval.  
 
 Supplementary table  7     Validity  of  ad hoc study (n = 20) 
 
 3 mL barium 
first swallow 
Pharyngeal Residue 
After Initial Swallowing 
3 mL barium 
mean of three swallows 
Pharyngeal Residue 
After Initial Swallowing 
10 ml barium 
first swallow 
Pharyngeal Residue 
After Initial Swallowing 
ALSFRS-R 
Total score 
-0.044 
(0.855) 
-0.273 
(0.244) 
-0.372 
(0.106) 
ALSFRS-R 
bulbar subscores 
-0.041 
(0.865) 
-0.232 
(0.325) 
-0.249 
(0.290) 
Limb Norris score 0.226 (0.337) 
0.085 
(0.721) 
-0.014 
(0.954) 
Norris bulbar score -0.149 (0.529) 
-0.203 
(0.390) 
-0.165 
(0.486) 
SBMAFRS 
Total score 
0.073 
(0.761) 
-0.097 
(0.684) 
-0.203 
(0.391) 
SBMAFRS 
bulbar subscores 
-0.042 
(0.860) 
-0.232 
(0.325) 
-0.267 
(0.256) 
SWAL-QOL 
Symptom subscores 
-0.235 
(0.319) 
-0.457 
(0.043) 
-0.308 
(0.187) 
SDQ-J 
Total score 
0.386 
(0.093) 
0.509 
(0.022) 
0.315 
(0.175) 
SDQ-J 
Oral subscores 
0.326 
(0.160) 
0.482 
(0.031) 
0.297 
(0.203) 
SDQ-J 
Pharyngeal subscores 
0.432 
(0.057) 
0.559 
(0.010) 
0.388 
(0.091) 
 
 
 
 
 
 
 Supplementary table  7 (cont.) 
 
 3 mL barium 
first swallow 
Pharyngeal Residue 
After Piecemeal Deglutition
3 mL barium 
mean of three swallows 
Pharyngeal Residue 
After Piecemeal Deglutition
10 ml barium 
first swallow 
Pharyngeal Residue 
After Piecemeal Deglutition
ALSFRS-R 
Total score 
-0.034 
(0.886) 
-0.155 
(0.513) 
-0.141 
(0.553) 
ALSFRS-R 
bulbar subscores 
0.053 
(0.824) 
-0.073 
(0.759) 
0.126 
(0.597) 
Limb Norris score 0.136 (0.569) 
0.146 
(0.540) 
-0.105 
(0.660) 
Norris bulbar score 0.006 (0.981) 
-0.004 
(0.986) 
0.269 
(0.251) 
SBMAFRS 
Total score 
0.068 
(0.775) 
0.002 
(0.992) 
-0.035 
(0.883) 
SBMAFRS 
bulbar subscores 
-0.021 
(0.929) 
-0.125 
(0.599) 
0.098 
(0.682) 
SWAL-QOL 
Symptom subscores 
-0.265 
(0.259) 
-0.439 
(0.053) 
-0.129 
(0.589) 
SDQ-J 
Total score 
0.328 
(0.158) 
0.492 
(0.028) 
0.066 
(0.781) 
SDQ-J 
Oral subscores 
0.311 
(0.182) 
0.449 
(0.047) 
0.136 
(0.567) 
SDQ-J 
Pharyngeal subscores 
0.346 
(0.135) 
0.510 
(0.022) 
0.093 
(0.696) 
 
 
 
 
 
 
 Supplementary table  7 (cont.) 
 
 3 mL barium 
first swallow 
Piecemeal Deglutition 
3 mL barium 
mean of three swallows 
Piecemeal Deglutition 
10 ml barium 
first swallow 
Piecemeal Deglutition 
ALSFRS-R 
Total score 
-0.107 
(0.655) 
-0.341 
(0.141) 
-0.307 
(0.189) 
ALSFRS-R 
bulbar subscores 
-0.170 
(0.472) 
-0.398 
(0.083) 
-0.461 
(0.041) 
Limb Norris score 0.061 (0.797) 
-0.173 
(0.466) 
-0.065 
(0.786) 
Norris bulbar score -0.416 (0.068) 
-0.494 
(0.027) 
-0.269 
(0.252) 
SBMAFRS 
Total score 
-0.103 
(0.666) 
-0.355 
(0.125) 
-0.289 
(0.217) 
SBMAFRS 
bulbar subscores 
-0.081 
(0.733) 
-0.334 
(0.150) 
-0.369 
(0.109) 
SWAL-QOL 
Symptom subscores 
-0.122 
(0.609) 
-0.180 
(0.447) 
-0.426 
(0.061) 
SDQ-J 
Total score 
0.162 
(0.495) 
0.155 
(0.514) 
0.318 
(0.172) 
SDQ-J 
Oral subscores 
0.156 
(0.511) 
0.227 
(0.336) 
0.421 
(0.065) 
SDQ-J 
Pharyngeal subscores 
0.224 
(0.342) 
0.188 
(0.428) 
0.320 
(0.170) 
Upper number denotes Spearman’s R; lower number with parenthesis denotes P value. 
Abbreviations: ALSFRS-R = revised amyotrophic lateral sclerosis functional rating scale; SBMAFRS = spinal and bulbar muscular 
atrophy functional rating scale; SWAL-QOL = a questionnaire on swallowing problems in daily life; SDQ-J = swallowing 
disturbance questionnaire-Japanese. 
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